Estrogen receptor a (ERa) is a transcription factor that regulates expression of target genes in a ligand-dependent manner. Activation of gene expression is mediated by two transcription activation functions AF-1 and AF-2, which act in a promoter-and cell-speci®c manner. Whilst AF-2 activity is regulated by estrogen (E2) binding, the activity of AF-1 is additionally modulated by phosphorylation at several sites. One of these phosphorylation sites, serine 118 (S118) is of particular interest as its mutation signi®cantly reduces ERa activity. Previous studies have shown that S118 can be phosphorylated by the ERK1/2 mitogen activated protein kinases (MAPK) and by the cyclindependent protein kinase Cdk7. In this study we use antisera that speci®cally recognize ERa phosphorylated at S118 to demonstrate that MAPK phosphorylates S118 in a ligand-independent manner, whereas Cdk7 mediates E2-induced phosphorylation of S118. E2 stimulation of S118 phosphorylation was observed within 10 min of its addition and was maximal at 10 77 M E2. S118 phosphorylation was maximal at 30 min but then declined, such that by 180 min following E2 addition little S118 phosphorylation was evident. S118 phosphorylation was also induced by the partial estrogen antagonist 4-hydroxytamoxifen, but not by the complete antagonist ICI 182, 780. S118 phosphorylation upon addition of the MAPK inducers EGF or PMA followed the expected time courses. Finally, we show that ERa is phosphorylated at S118 in vivo using immunoblotting of extracts prepared from a series of ERa-positive breast tumours.
Estrogen receptor a (ERa) is a transcription factor that regulates expression of target genes in a ligand-dependent manner. Activation of gene expression is mediated by two transcription activation functions AF-1 and AF-2, which act in a promoter-and cell-speci®c manner. Whilst AF-2 activity is regulated by estrogen (E2) binding, the activity of AF-1 is additionally modulated by phosphorylation at several sites. One of these phosphorylation sites, serine 118 (S118) is of particular interest as its mutation signi®cantly reduces ERa activity. Previous studies have shown that S118 can be phosphorylated by the ERK1/2 mitogen activated protein kinases (MAPK) and by the cyclindependent protein kinase Cdk7. In this study we use antisera that speci®cally recognize ERa phosphorylated at S118 to demonstrate that MAPK phosphorylates S118 in a ligand-independent manner, whereas Cdk7 mediates E2-induced phosphorylation of S118. E2 stimulation of S118 phosphorylation was observed within 10 min of its addition and was maximal at 10 77 M E2. S118 phosphorylation was maximal at 30 min but then declined, such that by 180 min following E2 addition little S118 phosphorylation was evident. S118 phosphorylation was also induced by the partial estrogen antagonist 4-hydroxytamoxifen, but not by the complete antagonist ICI 182, 780. S118 phosphor
Introduction
Estrogen receptor a (ERa) is a member of the nuclear receptor superfamily of transcription factors that are activated upon binding small lipophilic molecules. The superfamily includes receptors for androgen, glucocorticoid, progesterone, vitamin D3, thyroid hormone and retinoic acid, as well as receptors activated by peroxisome proliferators, bile acid-, prostaglandin-and benzoate-activated receptors (Blumberg and Evans, 1998; Makishima et al., 1999; Mangelsdorf et al., 1995; Parks et al., 1999; Wang et al., 1999) . ERa is required for regulating the development and in the maintenance of the female and male reproductive systems, in bone maintenance and in the cardiovascular system, as well as being signi®cant for certain brain functions (e.g. see Couse and Korach, 1999) . A central role for ERa in breast cancer progression has also long been recognized. Over half of all breast cancers express ERa and around 70% of these respond to anti-estrogen (for example tamoxifen) therapy, clearly demonstrating the importance of ERa in breast cancer. However, a proportion of ERa-positive tumours do not respond to endocrine therapy and the majority of responders eventually become resistant. Most resistant tumours remain ERapositive and frequently respond to alternative endocrine treatment, indicative of a continued role for ERa in breast cancer cell proliferation Horwitz, 1994; McGuire, 1978; Robertson, 1996) . Augmentation of ERa activity in the presence of estrogen or anti-estrogens and/or ligand-independent activation of ERa could provide an important mechanism for resistance to endocrine therapies.
ERa stimulates transcription upon binding to estrogen response elements within the promoters of estrogenregulated genes. Two C4-type zinc ®ngers mediate DNA binding. The hormone or ligand-binding domain (LBD) is encoded within a region of about 300 amino acids and is bound by estrogens and anti-estrogens. The LBD also contains a ligand-activated transcription activation function, AF-2, as well as sequences required for ligand-dependent dimerisation. The N-terminal 180 amino acids contain transcription activation function AF-1. AF-1 and AF-2 can act independently and synergistically in a promoter-and cell-speci®c manner Gronemeyer, 1991; Tsai and O'Malley, 1994) . Mutational analysis has de®ned several important regions within the LBD of ERa, required for AF-2 activity. In particular an amphipathic helix near the C-terminus of nuclear receptors is essential for ligand-dependent transcriptional activity (Barettino et al., 1994; Danielian et al., 1992; Durand et al., 1994; Saatcioglu et al., 1993) . Crystallographic studies have shown that ligand binding results in the realignment of this helix, enabling interacting proteins to associate (Brzozowski et al., 1997; Shiau et al., 1998) . Determination of the LBD structures for a number of other nuclear receptors indicates that realignment of helix 12 upon ligand binding is a common feature of nuclear receptors (see Moras and Gronemeyer, 1998) . The liganddependent realignment of helix 12 enables recruitment of co-activators to the LBD and thereby facilitates transcription activation (Glass and Rosenfeld, 2000) .
Investigation of the mechanisms underlying the inhibition of ERa activity by partial anti-estrogens such as tamoxifen and pure antagonists such as ICI 164,384 have shown that the agonistic activity of tamoxifen results from activation of AF-1 but inhibition of AF-2, whilst ICI 164,384 prevents the activation of AF-1 and AF-2 (Berry et al., 1990; Lees et al., 1989; McDonnell et al., 1995; Metzger et al., 1995b) . Recent studies have further demonstrated that anti-estrogen binding results in helix 12 occupying the co-activator binding site, thereby preventing co-activator recruitment (Brzozowski et al., 1997; Shiau et al., 1998) .
Whilst several studies have demonstrated that ligand binding controls AF-2 activity, phosphorylation provides an important mechanism by which AF-1 activity is regulated. Phosphorylation sites at serine 104 (and/or 106), serine 118 and serine 167 modulate AF-1 activity (Ali et al., 1993b; Arnold et al., 1994; Le Go et al., 1994; Shao and Lazar, 1999; Smith, 1998) . Much interest has been generated by the ®nding that S118 can be phosphorylated by MAPK in vitro and by activation of the MAPK signal transduction pathway in vivo. Moreover, MAPK activation enables ligand-independent transactivation by ERa (Arnold et al., 1995; Bunone et al., 1996; Kato et al., 1995) . Furthermore, we have shown that Cdk7 phosphorylates S118 in an E2-dependent manner, resulting in considerable stimulation of ERa activity. A proportion of cellular Cdk7 is present as part of the basal transcription factor TFIIH. S118 phosphorylation by Cdk7 was dependent on a liganddependent interaction between AF-2 and TFIIH (Chen et al., 2000) . Increased ERa activity upon S118 phosphorylation by Cdk7 and/or MAPK could therefore, be responsible, at least in part for resistance to endocrine therapy in breast cancer.
Here we show that S118 is phosphorylated by MAPK in a ligand-independent manner, whereas Cdk7-stimulated phosphorylation is ligand-dependent. We describe antisera that speci®cally recognise human ERa phosphorylated at S118. Using these antisera ligand and growth factor stimulation of S118 phosphorylation is investigated. Finally, we demonstrate that these antisera can be used to detect human ERa phosphorylated at S118 in breast cancer cell lines and in breast cancer biopsies. The implications of these ®ndings for breast cancer are discussed.
Results
Human estrogen receptor a is phosphorylated at serine 118 in COS-1 cells Amino acids 50 ± 150 of ERa have previously been shown to encode AF1 activity (Kobayashi et al., 2000; Metzger et al., 1995a) . Serine residues at positions 104/ 106 and 118 of ERa are the major sites of phosphorylation in this region and their mutation results in reduced transactivation by ERa (Ali et al., 1993b; Le Go et al., 1994) . COS-1 cells transiently transfected with an expression plasmid encoding ERa lacking the LBD (HE15; Figure 1a ) or substitution mutants of HE15 (HE15 104P,106A , HE15 118A ) were in vivo 32 P-labelled, followed by immunoprecipitation. Mutation of S104/ 106 or S118 resulted in a reduction in phosphorylation indicating that both sites are phosphorylated in COS-1 cells (Figure 1b) . It is possible that replacement of serine 104 by proline (HE15 104P,106A ) can aect phosphorylation of serine 118 by alteration in AF1 structure. However, mutation of serine 106 to alanine also reduced phosphorylation of this region in vivo (data not shown).
Human estrogen receptor a is phosphorylated by MAP kinase in vitro Examination of the amino acid sequences at S104, S106 and S118 suggested that they may be phosphorylated by proline-directed kinases such as MAPK (Gonzalez et al., 1991) . Reports of ligand-independent transcription activation by ERa, mediated by epidermal growth factor (EGF), insulin, insulin-like growth factor and phorbol esters further indicated that ERa might be phosphorylated by MAPK. Incubation with puri®ed, activated MAPK, ERK2, resulted in phosphorylation of puri®ed recombinant ERa. The levels of phosphorylation were similar in the absence or presence of E2 (Figure 1c, lanes 3, 4) , indicating that MAPK phosphorylation of ERa is not ligand-dependent. This was further supported by the ®nding that MAPK phosphorylation of ERa was unaected by the anti-estrogens 4-hydroxytamoxifen (OHT) and only slightly reduced in the presence of the pure antiestrogen ICI 182,780 (ICI) (Figure 1c, lanes 5, 6) . Calculation of the number of phosphates incorporated by cutting out the bands and determining the radioactivity incorporated following phosphorylation by MAPK showed that each ERa molecule is labelled with three phosphates in the absence of ligand or in the presence of E2 or OHT (ERa : phosphate ratios of 1 : 3.2, 1 : 3.4 and 1 : 3.0, respectively). In the presence of ICI, however, the ratio of ERa : phosphate was reduced to 2.3. These results suggest that MAPK phosphorylates ERa at multiple sites in vitro.
In order to determine which regions of ERa can be phosphorylated by MAPK in vitro, COS-1 cells were transfected with expression vectors containing the full length ERa coding region (HEG0), HEG19 (lacking amino acids 1 ± 180) or HE15 (Figure 1a ). The cells were harvested and lysed 72 h after transfection. Immunoprecipitates were incubated with [g 32 P]ATP, in the presence of MAPK. HEG0 and HE15 were phosphorylated, whereas HEG19 was not phosphorylated by MAPK, indicating that MAPK can phosphorylate ERa in vitro and does so on site(s) present within amino acids 1 ± 180 (data not shown).
Mutation of S118 signi®cantly reduced phosphorylation of ERa by MAPK (a weak signal was detectable following long exposures) ( Figure 1d , compare lanes 2, 4). Interestingly, mutation of HEG0 104P,106A also reduced the level of phosphorylation ( Figure 1d , lane 3), whereas HEG0 104P,106A,118A was not detectably phosphorylated. Mutation of S167 had no obvious eect on phosphorylation by MAPK. In agreement with our previous ®ndings mutation of S118 was sucient to prevent phosphorylation of ERa by puri®ed TFIIH. Mutation of S104, S106 or S167 had no eect on ERa phosphorylation by TFIIH ( Figure  1d lanes 7 ± 11).
Human estrogen receptor a is phosphorylated at serine 118 in a ligand-dependent manner by Cdk7 and in a ligand-independent manner by MAPK in vivo
In vivo
32 P-labelling of ERa transiently transfected into COS-1 cells shows that E2 treatment stimulates ERa phosphorylation. Co-transfection of Cdk7 signi®cantly increased ERa phosphorylation in the presence, but not in the absence of E2 (Figure 2a ,b). ERa phosphorylation was not stimulated when mutant Cdk7 (Cdk7M) was co-transfected along with ERa. Indeed, Cdk7M inhibited S118 phosphorylation (Figure 2a lanes 7, 8) . Stimulation of ERa phosphorylation by Cdk7 was prevented if S118 was mutated (Figure 2c, d) , indicating that S118 is the sole target for Cdk7 phosphorylation by Cdk7 in vivo.
In order to investigate the ligand-dependence of S118 phosphorylation by MAPK in vivo COS-1 cells were 118A (lane 4) were immunoprecipitated using monoclonal antibody B10. The immunoprecipitates were run on 10% SDS ± PAGE, transferred to nitrocellulose and immunoprobed with B10. HE15 and mutants were revealed using the alkaline phosphatase staining method (see Materials and methods) and autoradiographed. (c) Puri®ed recombinant ERa was phosphorylated in the presence (lanes 3 ± 6) or absence (lane 2) of puri®ed, activated ERK2/MAPK in vitro. 17b-estradiol (E2, lane 4), 4-hydroxytamoxifen (OHT, lane 5) or ICI 182,780 (ICI, lane 6), prepared in ethanol, were present at a ®nal concentration of 100 mM, as indicated. An equal volume of ethanol was added to the no ligand control (lanes 1 ± 3). The phosphorylation reaction performed in the absence of puri®ed ERa served as an additional control (lane 1). The phosphorylation reactions were subjected to SDS ± PAGE, immunoblotting and autoradiography as in part (b). (d) Immunoprecipitates of extracts from transiently transfected COS-1 cells were phosphorylated by incubation with puri®ed, activated ERK2/MAPK (lanes 1 ± 6) or TFIIH (lanes 7 ± 11) and processed as in (c). E2 (100 mM) was present throughout the procedure. Lane 1 was a control extract of pSG5-transfected cells transiently transfected with HEG0, together with constitutively active MAPKK (MAPKKEE) or ERK-MEK (ERK2-MEK1 fusion that gives constitutive ERK2 activity; Robinson et al., 1998) (Figure 2e,f) . Co-transfection with MAPKKEE stimulated ERa phosphorylation approximately six-fold in the absence or presence of E2. Similar results were obtained with ERK-MEK. Mutation of S118 prevented MAPKK or ERK-MEK stimulation of ERa phosphorylation. As expected co-transfection of dominant-negative MAPKK (MAPKKDM) did not stimulate ERa phosphorylation in the absence of ligand, but had no eect on E2-stimulated S118 phosphorylation. Taken together these results indicate that MAPK phosphorylates ERa at S118 in vivo in an E2-dependent manner.
Development of antisera for detection of phosphorylated serine 118
Antisera that recognize speci®c phosphorylated residues facilitate investigation of the signalling pathways regulating phosphorylation of the protein of interest. In order to investigate the utility of antisera speci®c for ERa phosphorylation sites, we raised antisera against a peptide containing amino-acid residues 112 ± 124 (Figure 1a) and containing phospho-serine at position 118. The speci®city of the antisera (designated a-PS118) was tested by immunoblotting of extracts from COS-1 cells transiently transfected with pSG5, HE15, HE15 118A or HE15 118E ( Figure 3a) . Immunoblotting with B10 showed one major band and a weak, more slowly migrating band. A slower migrating band was not observed in the case of HE15 118A or HE15 118E , indicating that the slower migrating band represents HE15 phosphorylated at S118. Treatment with PMA 30 min prior to harvesting increased the intensity of the slower migrating band (Figure 3a lanes 2, 3) . Immunoblotting of the same extracts using a-PS118 detected a single band for HE15 and a more intense band in the presence of PMA, which migrated at the same position as the slower migrating band observed with B10 ( Figure 3, lanes 7, 8) . The faster migrating band detected with B10 was not seen with a-PS118. An even more slowly migrating band was also evident following PMA treatment of HE15 and may represent phosphorylation of S104/S106 and/or S167, in addition to S118 (Figure 3, lane 8) . Interestingly, HE15 118E , but not HE15
118A , was also detected by a-PS118 (Figure 3a , 118A (lanes 10 ± 13), together with MAPKKEE (lanes 4, 5, 11), MAPKKDM (lanes 6, 7, 12) or ERK-MEK (lanes 8, 9, 13), as shown ERa phosphorylation at serine 118 D Chen et al lanes 9, 10), suggesting that a negative charge at this position is sucient for recognition by a-PS118 and indicative of speci®city over unphosphorylated ERa (or at least ERa lacking a negative charge at this position). Note also that the HE15 118E signal detected with a-PS118 migrates faster than phosphorylated HE15 (Figure 3a , compare lanes 8 and 10). Competitions were performed using the unphosphorylated peptide (peptide 1) or the phosphorylated peptide (peptide 2) in a 10-fold molar excess over the a-PS118 antiserum. Incubation with the phosphorylated peptide prevented detection of phosphorylated HE15 (Figure 3a , lanes 16 ± 20), whereas incubation with the unphosphorylated peptide did not (Figure 3a, lanes 11 ± 15) .
Immunoblotting using a-PS118 antisera demonstrated that S118 phosphorylation is stimulated approximately ®vefold by 10 77 M E2 within 30 min, when compared to total ERa levels as determined using monoclonal antibody B10 (Figure 3b lanes 2, 3) . Cdk7 overexpression further increased E2-stimulated S118 phosphorylation by levels similar to those observed using in vivo 32 P-labelling ( Figure 3b ,c compare lanes 3 and 5). Cdk2, another proline-directed protein kinase, has been shown to phosphorylate ERa at S104/S106 (Rogatsky et al., 1999) . Moreover, Cdk2 is phosphorylated and thereby activated by Cdk7. Cdk2 overexpression did not aect S118 phosphorylation, suggestive of direct phosphorylation of S118 by 118A (lanes 4, 9, 14, 19) or HE15 118E (lanes 5, 10, 15, 20) were resolved by 10% SDS ± PAGE and immunoblotted with B10 (lanes 1 ± 5), a-PS118 (lanes 6 ± 10), a-PS118 incubated with the unphosphorylated peptide (peptide 1; lanes 11 ± 15) or the peptide containing phosphoserine at the position equivalent to S118 (peptide 2; lanes 16 ± 20). PMA (100 ng/ml) was added 30 min before harvesting (lanes 3, 8, 13, 18) . (b) COS-1 cells transfected with pSG5 (lane 1) or HEG0 (lanes 2 ± 7), together with Cdk2 (lanes 4, 5) or Cdk7 (lanes 6, 7) were treated with E2 (100 mM) or ethanol (7) for 30 min prior to harvesting. Cell extracts were immunoblotted using a-PS118 and B10. (d) COS-1 cells transfected with pSG5 (lane 1) or HEG0 (lanes 2 ± 4), together with Cdk7 (lane 3) or Cdk7M (lane 4) were treated with E2 (100 nM) prior to harvesting. Immunoblotting was performed as in (b). (f) COS-1 cells transfected with pSG5 (lane 1) or HEG0 (lanes 2 ± 10), together with MAPKKEE (lanes 5 ± 7) or CL100 (lanes 8 ± 10) were treated with EGF (100 ng/ml) or E2 (100 nM) for 30 min prior to harvesting. Immunoblotting using B10 and a-PS118 was performed as in (b). Immunoblots for active MAPK (P-MAPK/P-ERK1/2) and total MAPK (ERK2) were also performed using these extracts. (c, e, g) Data quanti®cation was performed using Molecular Analyst BioRad Phosphor-imager software. Bar charts show the relative levels of phosphorylation observed following correction for ERa levels. Levels of phosphorylation for HEG0 in the presence of E2 was taken as 1 and all other activities are shown relative to this Cdk7. As observed by in vivo labelling overexpression of a mutant Cdk7 (Cdk7M) did not stimulate S118 phosphorylation . Indeed a small reduction in S118 phosphorylation was observed, similar to that observed in the in vivo labelling experiments (compare Figures 2a  and 3d) .
Transfection of MAPKKEE stimulated S118 phosphorylation in the absence or presence of E2. Similarly, EGF stimulated S118 phosphorylation (Figure 3f,g) . Transfection of the MAPK phosphatase CL100 inhibited MAPKKEE-stimulated S118 phosphorylation, but did not aect E2-stimulated phosphorylation. The MAPK inducers EGF and PMA stimulated S118 phosphorylation, as expected (Figure 4a,b) and the MAPKK/MEK inhibitors PD98059 and U0126 inhibited this phosphorylation in line with their inhibition of MAPK activity (Figure 4c,d ).
Estrogen and 4-hydroxy-tamoxifen induce phosphorylation of ERa at S118
We next investigated whether S118 is phosphorylated in the presence of OHT and ICI. OHT stimulated S118 phosphorylation, albeit to around 30% of the level induced by E2, whereas no S118 phosphorylation was observed in the presence of ICI (Figure 4e ,f lanes 6 ± 9). Moreover, E2-and OHT-stimulated S118 phosphorylation was not inhibited by U0126. Finally, the Cdk7 inhibitor DRB substantially inhibited E2-stimulated, but not EGF-stimulated S118 phosphorylation. Taken together, the data presented in Figures 3 and 4 demonstrate that ligand-independent phosphorylation of S118 is mediated by the ERK1/2 MAPK signal transduction pathway, whereas E2-and OHT-induced phosphorylation is Cdk7-dependent.
To determine the dose response of S118 phosphorylation COS-1 cells transfected with HEG0 were treated with ligands at concentrations ranging from 10 713 to 10 76 M for 30 min prior to harvesting. As before, cell lysates were immunoblotted using monoclonal antibody B10 and a-PS118 to detect total ERa and ERa phosphorylated at S118, respectively. S118 phosphorylation was evident at a concentration of 10 712 M E2 (Figure 5a , lane 4) and peaked at 10 77 M E2 (Figure 5a , lane 7). S118 phosphorylation was induced by 10 78 M OHT and increased with increasing OHT concentrations. By contrast, no stimulation of S118 phosphorylation was observed even at a concentration of 10 76 M ICI (Figure 5a , lane 15).
Time course of S118 phosphorylation induced by E2, EGF and PMA An examination of the time course of S118 phosphorylation using 10 77 M E2 showed that S118 phosphorylation was induced within 10 min, peaked at 30 min and subsequently fell to base line levels by 180 min (Figure 5b ). EGF treatment resulted in S118 phosphorylation within 10 min, peaking at 30 min and a subsequent fall in phosphorylation levels (Figure 5c ). PMA treatment stimulated S118 phosphorylation within 10 min. Maximal phosphorylation was obtained between 15 and 30 min (Figure 5d ). The time course of S118 phosphorylation induced by EGF and PMA was therefore similar to the time course of MAPK induction by EGF and PMA that has been described in numerous studies.
High basal levels of S118 phosphorylation in breast cancer
In order to determine whether S118 phosphorylation is observed in breast cancer, lysates were prepared from a number of breast tumours previously determined as ERa-positive by immunohistochemistry (data not shown). Immunoblotting using a-PS118 and B10 did not enable ERa detection. Therefore, we immunoprecipitated tumour lysates using B10. Immunoblotting showed that in all cases ERa was phosphorylated at S118. The levels of S118 phosphorylation, however, diered between tumours, when compared with total ERa levels observed using B10 (Figure 6 ). These data demonstrate for the ®rst time that ERa is phosphorylated at S118 in vivo.
Discussion
Transcription activation by estrogen receptor a occurs through the actions of a N-terminal transcription activation function AF-1 and an E2-dependent transcription activation function AF-2 within the LBD. AF-1 contains three major phosphorylation sites at serines 104 and/or 106, serine 118 and serine 167 (Ali et al., 1993b; Arnold et al., 1994; Le Go et al., 1994) . Mutation of these residues signi®cantly reduces transactivation by ERa, indicating that phosphorylation plays an important role in regulating AF-1 activity. Here we show that S104 and/or S106, as well as S118 are phosphorylated in COS-1 cells, in agreement with previous ®ndings (Ali et al., 1993b; Le Go et al., 1994) . We also show that ERa is phosphorylated at serine 118 by MAPK in vitro, con®rming previous reports (Arnold et al., 1995; Kato et al., 1995) . However, in vitro phosphorylation of puri®ed, recombinant ERa indicates that ERa is phosphorylated on at least three sites by MAPK. In agreement with this, 2D phosphopeptide mapping showed that S104 and S106, as well as serine 118 can be phosphorylated by MAPK in vitro (data not shown). In vivo, phosphorylation stimulated by MAPK activators was lower when serines 104 and 106 were mutated compared to wild-type ERa. Mutation of serine 118 resulted in considerably greater reduction in phosphorylation, indicating that it is the major MAPK substrate in vivo (data not shown). In contrast to our ®ndings, Kato et al. (1995) did not detect phosphorylation of any residues other than S118 by MAPK in vitro. The reasons for these dierences in our results and those reported previously are not clear. Moreover, phosphorylation of S104 and/or S106 by Cdk2 has been demonstrated (Rogatsky et al., 1999) . Notwithstanding these dierences, our in vivo and in vitro ERa phosphorylation at serine 118 D Chen et al Figure 4 Detection of HEG0 phosphorylated using a-PS118. (a,c,e,g) Whole cell extracts from COS-1 cells transiently transfected with pSG5 (lanes 1) or HEG0 were immunoblotted and quantitation was performed as described for Figure 3 . EGF (100 ng/ml), PMA (100 ng/ml), E2, OHT or ICI (all at 100 nM) were added 30 min prior to harvesting. The MAPKK/MEK inhibitors PD98059 or U0126 or the Cdk7 inhibitor DRB were added 1 h prior to the addition of EGF, PMA, E2 or anti-estrogens. In each case an equal volume of vehicle was added as appropriate. (b,d,f,h) Data quantitation was performed as in Figure 4 results show that S118 is the major site in ERa for MAPK phosphorylation, in agreement with previous reports.
Since our results and those of others (Ali et al., 1993b; Bunone et al., 1996; Kato et al., 1995) indicated that S118 is a major ERa phosphorylation site we raised antisera that speci®cally recognize ERa phosphorylated at S118. The antisera detected wild-type ERa but not a mutant in which S118 was replaced by an alanine. PMA treatment resulted in greater intensity of the band detected, consistent with S118 phosphorylation by MAPK. Furthermore, the band detected with a-PS118 migrated at the same position as the slower migrating band observed with monoclonal antibody B10, consistent with it representing a , EGF (100 ng/ml) or PMA (100 ng/ml) were added for varying lengths of time prior to harvesting as shown. Quantitation was performed as described for Figure 3 , except that the highest level of S118 phosphorylation observed within each experiment was taken as 1.0. All other activities are shown relative to this in the form of a line graph Figure 6 Estrogen receptor a is phosphorylated at serine 118 in vivo. Lysates prepared from six ERa-positive breast tumours were immunoprecipitated using monoclonal antibody B10. Immunoprecipitates were divided in two and immunoblotted using a-PS118 (top panel) or B10 (bottom panel). Whole cell extracts of the ERapositive breast cancer cell line MCF-7 grown in the absence of ligand or stimulated for 30 min with E2 (10 77 M) and PMA (100 ng/ml) (E+P) were used as controls for S118 phosphorylation ERa phosphorylation at serine 118 D Chen et al hyperphosphorylated form of the receptor (Figure 3a) . Reduced ERa mobility due to S118 phosphorylation in COS-1 cells has previously been described (Joel et al., 1998) . These results, together with competitions using phosphorylated and unphosphorylated peptide demonstrate that a-PS118 speci®cally detects ERa phosphorylated at S118. Using these antisera we show here that the EGFand PMA-mediated phosphorylation of serine 118 follows a time course similar to that observed for MAPK activation, indicating that the EGF-and PMAmediated phosphorylation of ERa is mediated by MAPK in vivo. Inhibition of S118 phosphorylation by MAPKK/MEK inhibitors, as well as by CL100 provides further evidence to con®rm this (Figure 4) . S118 phosphorylation was detectable at a concentration of 10 712 M E2 and was maximal at 10 77 M, with 50% of maximal phosphorylation being observed at around 0.5 nM (the K D of ERa is *0.5 nM (e.g. see Green et al., 1986) , suggesting that the kinetics of S118 phosphorylation in response to E2 follow the kinetics of E2 binding by ERa. The partial agonist 4-hydroxytamoxifen also induced phosphorylation of S118, albeit at greater concentrations than E2. However, the complete antagonist ICI 182,780 did not induce phosphorylation of ERa. This is interesting given that E2 and OHT are able to activate AF-1 whilst ICI is not. It appears, therefore, that the conformational changes in the receptor protein brought about by E2 and OHT (but not ICI) binding which enable transactivation by AF-1 also stimulate phosphorylation of S118.
In addition to phosphorylation by MAPK, we have shown that S118 can be phosphorylated by the cyclindependent kinase Cdk7. Cdk7 together with cyclin H and an accessory protein MAT1 represents the Cdk activating kinase (CAK) in mammalian cells. A small proportion of CAK forms part of the basal transcription factor TFIIH and phosphorylates the C-terminal domain of RNA polymerase II. We showed that a ligand-dependent interaction between TFIIH and the ERa LBD is required for S118 phosphorylation by Cdk7 (Chen et al., 2000) . Here we show that the E2-and OHT-induced phosphorylation of S118 is not inhibited by U0126, demonstrating that ligand-induced S118 phosphorylation is not mediated by MAPK. Furthermore, the Cdk7 inhibitor DRB (Yankulov et al., 1995) inhibited S118 phosphorylation, con®rming that Cdk7 mediates the ligand-induced phosphorylation.
Interestingly, the estrogen and anti-estrogen-induced phosphorylation of ERa have recently been shown to be mediated by a protein kinase(s) other than MAPK (Joel et al., 1998) . These authors utilised the observation that phosphorylation of ERa results in reduced electrophoretic mobility of the protein. On the basis of this observation they examined the phosphorylation kinetics of S118 phosphorylation in the breast cancer cell line MCF-7. In their study, however, ICI treatment resulted in the appearance of the slower migrating ERa, consistent with phosphorylation of S118 upon ICI treatment. It is also possible that S118 phosphorylation in response to estrogens and anti-estrogens diers according to cell type. Indeed, in chicken embryonal ®broblast (CEF) cells S118 does not appear to be phosphorylated (Ali et al., 1993b; and unpublished results) . Nevertheless, in agreement with our ®ndings in COS-1 cells, the results of Joel et al. (1998) indicate that in MCF-7 cells the E2-mediated phosphorylation of S118 is also independent of MAPK activity.
Our results suggest that S118 is a target for phosphorylation by Cdk7 in response to estrogen and in a ligand-independent manner by the MAPK signal transduction pathway in response to cell surface signals. We have also demonstrated that MAPK phosphorylates S104 and/or 106 in vitro and in vivo, whilst phosphorylation of S104/S106 by Cdk2 has been demonstrated (Rogatsky et al., 1999) . Numerous studies have demonstrated that phosphorylation within AF-1 is important for its activity. Our results demonstrating that distinct cellular signalling pathways converge at AF-1 is further con®rmation of this.
Despite the fact that the E2-induced phosphorylation of S118 does not appear to involve MAPK, our data and those of others show that induction of MAPK activity leads to increased S118 phosphorylation, resulting in ligand-independent transactivation by ERa. MAPK activity is elevated in breast tumours over benign breast, often accompanied by upregulation of MAPK gene expression (Coutts and Murphy, 1998; Sivaraman et al., 1997) . Given the importance of ERa expression in breast cancer progression and in treatment, ligand-independent activation of ERa by MAPK phosphorylation of S118 (Bunone et al., 1996) , raises the possibility that S118 phosphorylation by MAPK could result in resistance to endocrine therapy. Indeed, immunohistochemical analysis of breast cancers showed an association between phosphorylated (active) MAPK and poor response to anti-hormonal therapy (Gee et al., 2001) . Antisera that speci®cally detect ERa phosphorylated at S118 should be an important new tool for examining the phosphorylation status of ERa in breast cancer and may aid in predicting resistance to endocrine therapy.
Materials and methods

Expression plasmids
The expression vector pSG5 and its derivatives expressing HEG0 and HE15 have previously been described as have the mutants shown in Figure 1a and 17M-ERE-globin-CAT (Ali et al., 1993b; Berry et al., 1990; Tora et al., 1989b; Webster et al., 1988) . HE15 104P,106A,118A was generated by site-directed mutagenesis of HE15 104P,106A , using the oligonucleotide previously described (Ali et al., 1993b) . MAPKKDM (A217 mutant of MAPKK/MEK1) and MAPKKEE expression plasmids were kind gifts of Prof. C. Marshall and have been described (Alessi et al., 1994; Howe et al., 1992) . The CL100 expression plasmid was obtained from Dr S Keyse (Alessi et al., 1993; Keyse and Emslie, 1992) . The constitutively active ERK2 (an ERK2-MEK1 fusion) was provided by Dr M Cobb (Robinson et al., 1998) . Cdk7 and mutant Cdk7 (Cdk7M) were provided by Dr E Nigg (Tassan et al., 1994) and have been described before (Chen et al., 2000) . Cdk2 was cloned into pSG5 from a clone provided by Dr G Peters.
Cell transfection, in vivo 32 P-labelling and immunoprecipitation COS-1 cells were maintained in Dulbecco's modi®ed Eagle's Medium (DMEM) (Gibco ± BRL), supplemented with 5% fetal calf serum (FCS). 50% con¯uent 10 cm plates were transfected using the calcium phosphate technique (Tora et al., 1989a) . 5.0 mg of each expression vector was transfected together with human placental DNA (Sigma, UK) to make a total of 20 mg of DNA. The precipitate was removed after 16 ± 20 h, the cells were rinsed with DMEM and fresh medium was added. After a further 44 ± 48 h the cells were rinsed and harvested in chilled phosphate-buered saline, lysed by three cycles of freeze-thaw (7808C/08C) in 400 mM KCl, 20 mM Tris-HCl pH 7.5, 2 mM DTT, 2 mM Na 2 EDTA, 20% glycerol, 0.18 mg/ml PMSF and 1.25 mg/ml of leupeptin, aprotinin, pepstatin, antitrypsin and chymostatin. The extracts were cleared by centrifugation at 13 000 g for 20 min at 48C to remove cell debris. For in vivo labelling of transfected cells the medium was replaced with phosphate-free DMEM, supplemented with 5% dialysed fetal calf serum 40 h after washing o the calcium phosphate precipitates. After 4 h in the absence of phosphate ligands were added, as required, followed by the addition of 1 mCi [ 32 P]orthophosphate (Amersham International). The cells were labelled for 1 h, harvested and processed as above.
Immunoprecipitations were performed using B10 or F3 monoclonal antibodies as described (Ali et al., 1993a,b) . In vivo-labelled proteins were immunoprecipitated, resolved by SDS ± PAGE, electrotransferred to nitro-cellulose, followed by immunoprobing using B10 or F3 monoclonal antibodies, as appropriate, according to procedures described previously (Ali et al., 1993b) .
For experiments in which estrogen (17b-estradiol (E2)) or anti-estrogens (4-hydroxytamoxifen (OHT) or ICI 182,780 (ICI)) treatments were performed, the cells were maintained throughout in DMEM without phenol red (Berthois et al., 1986) , supplemented with 5% dextran-coated charcoaltreated FCS (Horwitz et al., 1978) . E2, OHT and ICI, prepared in ethanol, were added at the concentrations and length of time indicated in the text and ®gure legends. Ethanol was added to the no ligand controls. The phorbol ester PMA (100 ng/ml) or EGF (100 ng/ml), were also added for the lengths of time indicated in the text, as appropriate.
In vitro phosphorylation assays
Whole cell extracts from COS-1 cells transfected with pSG5, HEG0 or its derivatives were immunoprecipitated as above. The immunoprecipitates were washed with kinase buer (30 mM Tris-HCl pH 8.0, 20 mM MgCl 2 , 2 mM MnCl 2 ), then 30 ml kinase assay buer plus 10 mM ATP, 1 mCi [g 32 P]ATP and activated, puri®ed MAPK were added. The reactions were incubated at 308C for 30 min and stopped by addition of SDS ± PAGE sample buer. Labelled proteins were resolved by SDS ± PAGE, gels were dried down and autoradiographed. In the case of puri®ed recombinant ERa (Calbiochem), 0.01 pmoles of puri®ed ERa was incubated with MAPK in the kinase buer and processed as above. In vitro phosphorylation using puri®ed TFIIH was performed as described (Chen et al., 2000) .
Preparation of antisera specific to phosphorylated serine 118 and the characterization A peptide corresponding to amino-acids 112 ± 124 of ERa with the sequence [C]-HPPPQL p SPFLQPH (peptide 2) containing a N-terminal cysteine residue for coupling and phosphorylated serine ( p S) was synthesized, HPLC-puri®ed and its purity con®rmed by mass spectrometric analysis. The peptide was coupled to Keyhole Limpet haemocyanin and rabbits were inoculated using standard protocols. The peptides were synthesized and the antisera prepared by Genosys, UK. For competition experiments to determine speci®city immunoblotting was performed by incubating the blots with the primary antibody, in the presence of 10-fold molar excess of the phosphorylated peptide or a peptide with the sequence shown above but containing unphosphorylated serine.
Examination of the phosphorylation status of serine 118 using the phospho-S118 antisera (a-PS118) in response to MAPK activators, estrogens and anti-estrogens was performed using E2, OHT and ICI at a ®nal concentration of 10 77 M for 30 min prior to harvesting, unless otherwise speci®ed in the text and ®gure legends. The no ligand controls contained an equal volume of the solvent, ethanol. PD98059 (50 mM), U0126 (25 mM) and 5,6-Dichloro-1-beta-Dribofuranosylbenzimidazole (DRB, 100 mM) were prepared in ethanol or DMSO, as described in manufacturers' protocols and added 30 min or 1 h prior to the addition of E2 or antiestrogens. Immunoblotting using antibodies to MAPK (UBI, UK) and phosphorylated MAPK (Promega, UK) were performed according to manufacturers' protocols.
Breast tumours
Breast tumour tissues (typically 0.5 ± 1 g), previously shown to be ERa-positive using immunohistochemistry, were ground in liquid nitrogen. Modi®ed RIPA buer (50 mM Tris.HCl, pH 7.5, 2.5% sodium deoxycholate, 1% NP40, 20 mM Na 2 MoO 4 , 20 mM NaF, 2 mM Na 3 VO 4 , 20 mM b-glycerophophate, 200 nM okadaic acid, 1 mM EDTA and protease inhibitor cocktail (Roche) was added (250 ml/100 mg of tissue). Following freeze thaws (from liquid nitrogen/ice) and centrifugation at 14K for 20 min protein concentrations were determined using the Bradford method. Immunoprecipitations were performed using 1.5 mg of total protein with anti-ERa (B10).
